1. Home
  2. LNG vs NNVC Comparison

LNG vs NNVC Comparison

Compare LNG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cheniere Energy Inc.

LNG

Cheniere Energy Inc.

HOLD

Current Price

$197.98

Market Cap

46.4B

Sector

Utilities

ML Signal

HOLD

NNVC

NanoViricides Inc.

HOLD

Current Price

$1.21

Market Cap

24.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNG
NNVC
Founded
1983
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.4B
24.4M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
LNG
NNVC
Price
$197.98
$1.21
Analyst Decision
Strong Buy
Analyst Count
12
0
Target Price
$265.83
N/A
AVG Volume (30 Days)
2.1M
327.9K
Earning Date
02-19-2026
02-13-2026
Dividend Yield
1.12%
N/A
EPS Growth
14.15
N/A
EPS
17.92
N/A
Revenue
$18,937,000,000.00
N/A
Revenue This Year
$30.79
N/A
Revenue Next Year
$13.52
N/A
P/E Ratio
$11.04
N/A
Revenue Growth
21.55
N/A
52 Week Low
$186.20
$0.94
52 Week High
$257.65
$2.23

Technical Indicators

Market Signals
Indicator
LNG
NNVC
Relative Strength Index (RSI) 51.41 47.79
Support Level $188.13 $1.20
Resistance Level $192.21 $1.31
Average True Range (ATR) 3.21 0.07
MACD 1.39 0.00
Stochastic Oscillator 85.87 41.38

Price Performance

Historical Comparison
LNG
NNVC

About LNG Cheniere Energy Inc.

Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Share on Social Networks: